Abstract
We investigated block of the α1Cb subunit of L-type calcium channels by dihydropyridines (DHPs) in which a permanently charged or neutral head group was linked to the active DHP moiety by a spacer chain containing ten methylene (−CH2) groups. We compared the sensitivity of channel modulation by the charged (DHPch) and neutral (DHPn) forms to specific α1Cb mutations in domains IIIS5, IIIS6, and IVS6, which had previously been shown to reduce channel modulation by the neutral DHP (+)-isradipine. The effects of these mutations were studied on channel block recorded from polarized (−80 mV) and depolarized (−40 mV) holding potentials (HPs). We found that channel block by DHPn was markedly reduced at both HPs by each mutation studied. In contrast, channel block by DHPch was only modestly reduced by mutations in IIIS6 and IVS6 for block from either −40 mV or −80 mV. Replacement of IIIS5 Thr1061 by Tyr, which abolished block by DHPn in an HP-independent manner, had little effect on channel block by DHPch recorded from −40 mV. However, this mutation markedly reduced DHPch block of currents recorded from a −80 mV HP. Inhibition of current by DHPch was not markedly use-dependent, in contrast with block by verapamil, another charged calcium channel blocker. These results suggest that the presence of a permanently charged head group restricts the access of the attached DHP moiety to a subset of interaction residues on the α1C subunit in a voltage-dependent manner. Furthermore, these restricted interactions confer distinct functional properties upon the charged DHP molecules.
Footnotes
-
Send reprint requests to: Dr. Robert S. Kass, Department of Pharmacology, College of Physicians & Surgeons of Columbia University, 630 West 168th St., New York, NY 10032. E-mail:rsk20{at}columbia.edu
-
↵1 This work was supported by U.S. Public Health Service Grant HL-21922–20, Deutsche Forschungsgemeinschaft, and Fond der Chemie.
-
↵2 Current affiliation: Institut für Pharmakologie and Toxikologie der TU München, Biedersteiner Strasse 29, 80802 München, Germany.
-
↵3 Current affiliation: Department of Pharmacology, College of Physicians & Surgeons of Columbia University, 630 West 168th St., New York, NY 10032.
-
↵4 Current affiliation: School of Pharmacy, SUNY at Buffalo, Buffalo, NY 14260.
-
↵5 On leave from Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Vlarska 5, 833 04 Bratislava, Slovakia.
- Abbreviations:
- DHP
- dihydropyridine
- DHPch
- custom-synthesized charged dihydropyridine used in this study
- DHPn
- custom-synthesized neutral dihydropyridine used in this study
- HP
- holding potential
- WT
- wild-type α1cb
- P-region
- pore region
- Received September 23, 1998.
- Accepted January 20, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|